Innate Immunotherapeutics Limited (ASX Code:IIL) is pleased to confirm that the last patient enrolled into the Company's Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS) has now completed their last study related clinical visit.
CEO Simon Wilkinson commented, "This is an important milestone in the development of MIS416 and we have many parties to thank for helping us achieve it. In particular we express our gratitude to the investigators, coordinators, and nursing staff at the seven sites where the study has been conducted. Above all else, we say thank you to all those who participated in this significant study."
For further information please download PDF attached:
Download this document